Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Estring approved for marketing in U.S.

May 10, 1996

Muse safety and efficacy reported at urology meeting

May 10, 1996

Sildenafil demonstrates efficacy in erectile dysfunction Rx

May 10, 1996

AI-401 progresses to phase II

May 10, 1996

EU approval granted for Humalog

May 10, 1996

Sandoz synthesizes new antidiabetic agents

May 10, 1996

Yakult claims ACAT inhibitor from natural source

May 10, 1996

Hoechst claims bile acid sequestrants

May 10, 1996

Corydalin: ACAT inhibitor from natural source

May 10, 1996

Bone-regulatory activity of oncostatin M reported

May 10, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.